SCM
BCRX icon

Semanteon Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Semanteon Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-43,544
Closed -$330K – 29
2025
Q3 		$330K Buy
+43,544
New +$363K 0.41% 133
2025
Q2 		– Sell
-189,706
Closed -$1.42M – 118
2025
Q1 		$1.42M Sell
189,706
-8,054
-4% -$65K 0.77% 42
2024
Q4 		$1.49M Buy
197,760
+48,184
+32% +$366K 0.8% 6
2024
Q3 		$1.14M Buy
+149,576
New +$1.14M 0.77% 49

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Semanteon Capital Management's BCRX Position: Q4 2025 in Review

Semanteon Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 43,544 shares — an estimated $330K sold.

Semanteon Capital Management first reported a position in BCRX in Q3 2024 and held it in 4 quarters. The position peaked at $1.49M in Q4 2024. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Semanteon Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Semanteon Capital Management sold 43,544 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $330K.
  • Semanteon Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Semanteon Capital Management's BioCryst Pharmaceuticals position peaked at $1.49M in Q4 2024.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Semanteon Capital Management's 13F filing for Q4 2025, filed 10 Feb 2026.